Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immix Biopharma, Inc. (Nasdaq: IMMX) announced on March 10, 2023, that it has no exposure to Silicon Valley Bank or Silvergate Bank. This statement underscores the company’s financial stability amidst recent banking sector concerns. ImmixBio is a clinical-stage biopharmaceutical company focusing on Tissue-Specific Therapeutics (TSTx)™ aimed at treating oncology and immuno-dysregulated diseases. With its proprietary SMARxT Tissue-Specific™ Platform, ImmixBio is innovating in the treatment landscape by targeting tumor microenvironments to enhance therapeutic efficacy.
Details
News Market Reaction – IMMX
The recorded move for IMMX in the trading session of this news was +14.45%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LOS ANGELES, March 10, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today confirms that neither ImmixBio, nor any of its subsidiaries, have any exposure to Silicon Valley Bank (“SVB”) or Silvergate Bank.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio™) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases. Our proprietary SMARxT Tissue-Specific™ Platform produces drug candidates that circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all 3 components of the tumor micro-environment (TME). We believe ImmixBio’s TME Normalization™ technology severs the lifelines between the tumor and its metabolic and structural support. Learn more at www.immixbio.com
Investor Contact
Suzanne Messere
Stern Investor Relations
Suzanne.Messere@sternir.com
Company Contact
irteam@immixbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.